Key Highlights
- Veracyte, Inc. (NASDAQ:VCYT) traded at USD 23.69, down 54.9% in trading on November 5, 2026, per published market data, after results released on November 4, 2026.
- Third quarter Revenue rose 15% to USD 151.8 million, with GAAP Net Income of USD 31.5 million and adjusted EBITDA of USD 41.2 million, or 27.2% of revenue.
- Full-year 2026 testing revenue guidance was lowered to USD 571 million to USD 573 million from USD 576 million to USD 582 million, as Decipher Prostate Volume trailed expectations.
- Cash, cash equivalents and short-term investments stood at USD 370.5 million, and the board authorized up to USD 100 million of share repurchases over 12 months.
Guidance Cut Overshadows a Solid Quarter
Veracyte, Inc. (NASDAQ:VCYT) reported third quarter 2026 results on November 4, 2026, and the stock reaction came in trading on November 5, 2026. Total revenue rose 15% to USD 151.8 million from USD 131.9 million, and testing revenue rose 15% to USD 146.4 million. The trigger was the outlook: 2026 testing revenue guidance now sits at USD 571 million to USD 573 million, down from USD 576 million to USD 582 million. Total revenue guidance moved to USD 590 million to USD 593 million from USD 590 million to USD 596 million. The adjusted EBITDA Margin outlook of more than 26% was left unchanged.
What Management Said and How the Numbers Look
Chief Executive Marc Stapley said the company delivered solid results with strong profitability and cash generation, adding that Afirma outperformed while Decipher Prostate volume was below expectations. The company noted that the revised outlook includes minimal revenue contribution from recently launched tests. GAAP net income was USD 31.5 million, or 20.8% of revenue, with diluted GAAP EPS of USD 0.38 and non-GAAP diluted EPS of USD 0.51. Operating Cash Flow was USD 40.3 million. A guidance reduction matters because investors price diagnostics companies on volume growth in key tests, so a shortfall in one Franchise can reset the growth multiple even when profits rise.
Analyst Reaction, Risks and What to Watch
Leerink Partners lowered its rating on Veracyte, Inc. (NASDAQ:VCYT) to market perform from outperform on November 5, 2026, with a USD 35 price target, according to published coverage. Key risks include slower Decipher Prostate adoption, payer reimbursement for genomic tests, concentration in a few products, and uncertain uptake of newly launched tests. The size of the share price move is unusually large for a profitable company with USD 370.5 million of liquidity, and quoted intraday moves can change by the close. Investors will watch fourth quarter prostate test volumes and how quickly the repurchase program is used.
Where Things Stand
Veracyte, Inc. (NASDAQ:VCYT) fell sharply because a modest cut to testing guidance exposed weaker Decipher Prostate volume at a company priced for steady growth. The quarter itself was profitable and cash generative, with revenue up 15% and USD 370.5 million of liquidity, so the reaction reflects a reset in expectations rather than a deterioration in the balance sheet. The USD 100 million buyback offers some support but does not change the volume question. The next test is fourth quarter prostate test volume and whether management can restore the prior growth trajectory.






Please wait processing your request...